IM
IM
IM
0.1 Results
Factor | Detalis | Total |
N= | 262 | |
Gender | F | 45 (17.2%) |
M | 217 (82.8%) | |
Age | μ ±DS | 67.29 ±8.88 |
M (min:max) | 68.2 (45.2:86.1) | |
Year of diagnosis | μ ±DS | 2014.75 ±2.99 |
M (min:max) | 2015 (2008:2019) | |
Survival | μ ±DS | 23.70 ±22.4 |
M (min:max) | 17 (0:114) | |
Status | 0 | 83 (32.9%) |
1 | 159 (63.1%) | |
2 | 10 (4.0%) | |
MRI_diagnosis | 85 (32.6%) | |
CT_Diagnosis | 153 (58.6%) | |
US_Diagnosis | 87 (33.3%) | |
HCC_Screening_18months_before | 97 (37.3%) | |
US_Screening | 68 (30.2%) | |
MRI_Screening | 22 (9.8%) | |
CT_Screening | 39 (17.3%) | |
ASH | 130 (49.6%) | |
NAFLD | 106 (40.5%) | |
Cirrhosis | 218 (83.2%) | |
HCV | 57 (21.8%) | |
HBc | 20 (7.6%) | |
Diagnosis | NAFLD | 55 (21.0%) |
ASH | 79 (30.2%) | |
VIRAL | 77 (29.4%) | |
ASH & NAFLD | 51 (19.5%) | |
Diabetes | 98 (37.4%) | |
Hipertension | 134 (53.4%) | |
Hiperlipidemia | 43 (17.1%) | |
Smoking | 0 | 135 (52.9%) |
1 | 106 (41.6%) | |
2 | 14 (5.5%) | |
Alcohol_Consume | 0 | 162 (63.5%) |
1 | 76 (29.8%) | |
2 | 17 (6.7%) | |
BMI | μ ±DS | 27.98 ±5.31 |
M (min:max) | 27.3 (16.02:48.32) | |
Encephalopathy (acc. to CP score) | 1 | 239 (94.8%) |
2-3 | 13 (5.2%) | |
Ascites (acc. to CP score) | 1 | 203 (80.9%) |
2 | 30 (12.0%) | |
3 | 18 (7.2%) | |
Bilirubin total (µmol/L) | μ ±DS | 24.54 ±36.5 |
M (min:max) | 16 (3:413) | |
INR | μ ±DS | 1.16 ±0.188 |
M (min:max) | 1.12 (0.8:2.07) | |
Albumin (g/L) | μ ±DS | 32.75 ±5.78 |
M (min:max) | 33.5 (17:49.8) | |
CHILD | 1 | 159 (64.4%) |
2 | 75 (30.4%) | |
3 | 13 (5.3%) | |
CHILD_A | 159 (64.4%) | |
CHILD_B | 75 (30.4%) | |
CHILD_C | 13 (5.3%) | |
BCLC | 0 | 16 (6.1%) |
1 | 96 (36.8%) | |
2 | 74 (28.4%) | |
3 | 57 (21.8%) | |
4 | 18 (6.9%) | |
BCLC_0 | 16 (6.1%) | |
BCLC_1 | 96 (36.8%) | |
BCLC_2 | 74 (28.4%) | |
BCLC_3 | 57 (21.8%) | |
BCLC_4 | 18 (6.9%) | |
Resection | 52 (19.9%) | |
Transplant | 10 (3.8%) | |
TACE | 37 (14.2%) | |
TAE | 19 (7.3%) | |
RFA | 8 (3.1%) | |
MWA | 50 (19.2%) | |
SIRT | 9 (3.5%) | |
Sistemic_therapy | 55 (21.2%) | |
Curative_treatment | 97 (37.3%) | |
Loco_regional_therapies | 59 (22.7%) | |
No_treatment | 40 (15.4%) | |
Treatment | Curative | 97 (37.3%) |
Transplant | 10 (3.8%) | |
Loco-regional | 59 (22.7%) | |
Systemic | 54 (20.8%) | |
No treatment | 40 (15.4%) | |
Performance Status | 0 | 150 (58.6%) |
1 | 68 (26.6%) | |
2 | 25 (9.8%) | |
3 | 10 (3.9%) | |
4 | 3 (1.2%) | |
PS_0 | 150 (58.6%) | |
PS_1 | 68 (26.6%) | |
PS_2 | 25 (9.8%) | |
PS_3 | 10 (3.9%) | |
PS_4 | 3 (1.2%) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); | ||
Factor | Detalis | NAFLD | ASH | VIRAL | ASH & NAFLD | Total | Statistics |
Diagnosis | 55 (21.0%) | 79 (30.2%) | 77 (29.4%) | 51 (19.5%) | 262 | ||
Gender | F | 9 (16.4%) | 11 (13.9%) | 23 (29.9%) | 2 (3.9%) | 45 (17.2%) | V=0.24 (p=0.001) |
M | 46 (83.6%) | 68 (86.1%) | 54 (70.1%) | 49 (96.1%) | 217 (82.8%) | ||
Age | μ ±DS | 70.83 ±7.01 | 67.28 ±8.81 | 63.60 ±9.5 | 69.07 ±7.89 | 67.29 ±8.88 | Kruskal-Wallis: p<0.001 |
M (min:max) | 71.1 (50.9:86.1) | 67.6 (45.2:86) | 61.8 (45.5:83.9) | 69.7 (53.5:83.9) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2014.87 ±3.23 | 2015.05 ±3.22 | 2014.27 ±2.69 | 2014.86 ±2.78 | 2014.75 ±2.99 | Kruskal-Wallis: p=0.242 |
M (min:max) | 2015 (2008:2019) | 2016 (2008:2019) | 2015 (2009:2019) | 2015 (2009:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 21.93 ±23.9 | 23.50 ±23.6 | 25.20 ±20.7 | 23.80 ±21.7 | 23.70 ±22.4 | Kruskal-Wallis: p=0.585 |
M (min:max) | 14 (0:110) | 15 (0:114) | 20.5 (0:93) | 19.5 (0:85) | 17 (0:114) | ||
Status | 0 | 22 (40.7%) | 29 (38.2%) | 21 (29.2%) | 11 (22.0%) | 83 (32.9%) | V=0.12 (p=0.315) |
1 | 29 (53.7%) | 45 (59.2%) | 49 (68.1%) | 36 (72.0%) | 159 (63.1%) | ||
2 | 3 (5.6%) | 2 (2.6%) | 2 (2.8%) | 3 (6.0%) | 10 (4.0%) | ||
MRI_diagnosis | 18 (32.7%) | 24 (30.4%) | 28 (36.8%) | 15 (29.4%) | 85 (32.6%) | V=0.06 (p=0.792) | |
CT_Diagnosis | 33 (60.0%) | 47 (59.5%) | 42 (55.3%) | 31 (60.8%) | 153 (58.6%) | V=0.04 (p=0.915) | |
US_Diagnosis | 20 (36.4%) | 25 (31.6%) | 27 (35.5%) | 15 (29.4%) | 87 (33.3%) | V=0.06 (p=0.838) | |
HCC_Screening_18months_before | 23 (41.8%) | 23 (29.1%) | 37 (48.1%) | 14 (28.6%) | 97 (37.3%) | V=0.18 (p=0.043) | |
US_Screening | 17 (30.9%) | 14 (17.7%) | 27 (35.1%) | 10 (71.4%) | 68 (30.2%) | V=0.28 (p<0.001) | |
MRI_Screening | 6 (10.9%) | 7 (8.9%) | 5 (6.5%) | 4 (28.6%) | 22 (9.8%) | V=0.17 (p=0.082) | |
CT_Screening | 9 (16.4%) | 14 (17.7%) | 12 (15.6%) | 4 (28.6%) | 39 (17.3%) | V=0.08 (p=0.696) | |
ASH | 0 | 79 (100%) | 0 | 51 (100%) | 130 (49.6%) | V=1.00 (p<0.001) | |
NAFLD | 55 (100%) | 0 | 0 | 51 (100%) | 106 (40.5%) | V=1.00 (p<0.001) | |
Cirrhosis | 42 (76.4%) | 70 (88.6%) | 62 (80.5%) | 44 (86.3%) | 218 (83.2%) | V=0.13 (p=0.237) | |
HCV | 0 | 0 | 57 (74.0%) | 0 | 57 (21.8%) | V=0.82 (p<0.001) | |
HBc | 0 | 0 | 20 (26.0%) | 0 | 20 (7.6%) | V=0.45 (p<0.001) | |
Diabetes | 35 (63.6%) | 18 (22.8%) | 19 (24.7%) | 26 (51.0%) | 98 (37.4%) | V=0.35 (p<0.001) | |
Hipertension | 35 (68.6%) | 35 (46.1%) | 25 (33.8%) | 39 (78.0%) | 134 (53.4%) | V=0.35 (p<0.001) | |
Hiperlipidemia | 16 (31.4%) | 12 (15.8%) | 2 (2.7%) | 13 (26.0%) | 43 (17.1%) | V=0.29 (p<0.001) | |
Smoking | 0 | 38 (70.4%) | 31 (39.2%) | 41 (57.7%) | 25 (49.0%) | 135 (52.9%) | V=0.38 (p<0.001) |
1 | 16 (29.6%) | 48 (60.8%) | 30 (42.3%) | 12 (23.5%) | 106 (41.6%) | ||
2 | 0 | 0 | 0 | 14 (27.5%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 47 (87.0%) | 31 (39.2%) | 65 (91.5%) | 19 (37.3%) | 162 (63.5%) | V=0.52 (p<0.001) |
1 | 7 (13.0%) | 48 (60.8%) | 6 (8.5%) | 15 (29.4%) | 76 (29.8%) | ||
2 | 0 | 0 | 0 | 17 (33.3%) | 17 (6.7%) | ||
BMI | μ ±DS | 30.61 ±4.98 | 26.26 ±4.15 | 26.22 ±5.44 | 30.35 ±5.22 | 27.98 ±5.31 | Kruskal-Wallis: p<0.001 |
M (min:max) | 30.44 (18.48:42.17) | 25.98 (18.63:38.74) | 25.25 (16.02:46.02) | 29.68 (20.34:48.32) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 51 (96.2%) | 73 (92.4%) | 69 (97.2%) | 46 (93.9%) | 239 (94.8%) | V=0.09 (p=0.561) |
2-3 | 2 (3.8%) | 6 (7.6%) | 2 (2.8%) | 3 (6.1%) | 13 (5.2%) | ||
Ascites (acc. to CP score) | 1 | 44 (84.6%) | 59 (74.7%) | 60 (84.5%) | 40 (81.6%) | 203 (80.9%) | V=0.14 (p=0.165) |
2 | 7 (13.5%) | 10 (12.7%) | 9 (12.7%) | 4 (8.2%) | 30 (12.0%) | ||
3 | 1 (1.9%) | 10 (12.7%) | 2 (2.8%) | 5 (10.2%) | 18 (7.2%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.88 ±18.2 | 27.42 ±37.6 | 15.69 ±10.7 | 33.12 ±61.2 | 24.54 ±36.5 | Kruskal-Wallis: p=0.006 |
M (min:max) | 18 (5:104) | 16 (3:286) | 12 (4:62) | 18 (6:413) | 16 (3:413) | ||
INR | μ ±DS | 1.16 ±0.162 | 1.19 ±0.222 | 1.12 ±0.163 | 1.19 ±0.184 | 1.16 ±0.188 | Kruskal-Wallis: p=0.049 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.08 (0.8:1.9) | 1.15 (0.99:1.96) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 33.01 ±4.59 | 31.73 ±6.24 | 34.33 ±5.51 | 31.79 ±6.14 | 32.75 ±5.78 | Kruskal-Wallis: p=0.037 |
M (min:max) | 33 (24:42) | 32.5 (20:42) | 35 (22:44) | 32 (17:49.8) | 33.5 (17:49.8) | ||
CHILD | 1 | 31 (64.6%) | 44 (55.7%) | 56 (77.8%) | 28 (58.3%) | 159 (64.4%) | V=0.15 (p=0.104) |
2 | 15 (31.2%) | 28 (35.4%) | 14 (19.4%) | 18 (37.5%) | 75 (30.4%) | ||
3 | 2 (4.2%) | 7 (8.9%) | 2 (2.8%) | 2 (4.2%) | 13 (5.3%) | ||
CHILD_A | 31 (64.6%) | 44 (55.7%) | 56 (77.8%) | 28 (58.3%) | 159 (64.4%) | V=0.19 (p=0.029) | |
CHILD_B | 15 (31.2%) | 28 (35.4%) | 14 (19.4%) | 18 (37.5%) | 75 (30.4%) | V=0.16 (p=0.102) | |
CHILD_C | 2 (4.2%) | 7 (8.9%) | 2 (2.8%) | 2 (4.2%) | 13 (5.3%) | V=0.11 (p=0.366) | |
BCLC | 0 | 2 (3.7%) | 9 (11.4%) | 3 (3.9%) | 2 (3.9%) | 16 (6.1%) | V=0.14 (p=0.271) |
1 | 21 (38.9%) | 26 (32.9%) | 33 (42.9%) | 16 (31.4%) | 96 (36.8%) | ||
2 | 15 (27.8%) | 22 (27.8%) | 17 (22.1%) | 20 (39.2%) | 74 (28.4%) | ||
3 | 13 (24.1%) | 14 (17.7%) | 21 (27.3%) | 9 (17.6%) | 57 (21.8%) | ||
4 | 3 (5.6%) | 8 (10.1%) | 3 (3.9%) | 4 (7.8%) | 18 (6.9%) | ||
BCLC_0 | 2 (3.7%) | 9 (11.4%) | 3 (3.9%) | 2 (3.9%) | 16 (6.1%) | V=0.14 (p=0.141) | |
BCLC_1 | 21 (38.9%) | 26 (32.9%) | 33 (42.9%) | 16 (31.4%) | 96 (36.8%) | V=0.10 (p=0.480) | |
BCLC_2 | 15 (27.8%) | 22 (27.8%) | 17 (22.1%) | 20 (39.2%) | 74 (28.4%) | V=0.13 (p=0.215) | |
BCLC_3 | 13 (24.1%) | 14 (17.7%) | 21 (27.3%) | 9 (17.6%) | 57 (21.8%) | V=0.10 (p=0.424) | |
BCLC_4 | 3 (5.6%) | 8 (10.1%) | 3 (3.9%) | 4 (7.8%) | 18 (6.9%) | V=0.10 (p=0.460) | |
Resection | 12 (21.8%) | 17 (21.5%) | 17 (22.4%) | 6 (11.8%) | 52 (19.9%) | V=0.10 (p=0.447) | |
Transplant | 0 | 3 (3.8%) | 5 (6.6%) | 2 (3.9%) | 10 (3.8%) | V=0.12 (p=0.291) | |
TACE | 7 (12.7%) | 9 (11.5%) | 13 (17.1%) | 8 (15.7%) | 37 (14.2%) | V=0.07 (p=0.761) | |
TAE | 5 (9.1%) | 5 (6.4%) | 4 (5.3%) | 5 (10.0%) | 19 (7.3%) | V=0.07 (p=0.717) | |
RFA | 2 (3.7%) | 1 (1.3%) | 5 (6.6%) | 0 | 8 (3.1%) | V=0.15 (p=0.131) | |
MWA | 11 (20.0%) | 13 (16.7%) | 15 (19.7%) | 11 (21.6%) | 50 (19.2%) | V=0.05 (p=0.909) | |
SIRT | 1 (1.8%) | 2 (2.6%) | 4 (5.3%) | 2 (3.9%) | 9 (3.5%) | V=0.07 (p=0.705) | |
Sistemic_therapy | 12 (21.8%) | 16 (20.5%) | 12 (15.8%) | 15 (29.4%) | 55 (21.2%) | V=0.11 (p=0.330) | |
Curative_treatment | 25 (45.5%) | 27 (34.6%) | 31 (40.8%) | 14 (27.5%) | 97 (37.3%) | V=0.13 (p=0.229) | |
Loco_regional_therapies | 12 (21.8%) | 16 (20.5%) | 18 (23.7%) | 13 (25.5%) | 59 (22.7%) | V=0.04 (p=0.918) | |
No_treatment | 6 (10.9%) | 16 (20.5%) | 11 (14.5%) | 7 (13.7%) | 40 (15.4%) | V=0.10 (p=0.461) | |
Treatment | Curative | 25 (45.5%) | 27 (34.6%) | 31 (40.8%) | 14 (27.5%) | 97 (37.3%) | V=0.12 (p=0.431) |
Transplant | 0 | 3 (3.8%) | 5 (6.6%) | 2 (3.9%) | 10 (3.8%) | ||
Loco-regional | 12 (21.8%) | 16 (20.5%) | 18 (23.7%) | 13 (25.5%) | 59 (22.7%) | ||
Systemic | 12 (21.8%) | 16 (20.5%) | 11 (14.5%) | 15 (29.4%) | 54 (20.8%) | ||
No treatment | 6 (10.9%) | 16 (20.5%) | 11 (14.5%) | 7 (13.7%) | 40 (15.4%) | ||
Performance Status | 0 | 34 (64.2%) | 45 (57.0%) | 40 (54.8%) | 31 (60.8%) | 150 (58.6%) | V=0.09 (p=0.885) |
1 | 13 (24.5%) | 20 (25.3%) | 22 (30.1%) | 13 (25.5%) | 68 (26.6%) | ||
2 | 4 (7.5%) | 8 (10.1%) | 8 (11.0%) | 5 (9.8%) | 25 (9.8%) | ||
3 | 2 (3.8%) | 5 (6.3%) | 1 (1.4%) | 2 (3.9%) | 10 (3.9%) | ||
4 | 0 | 1 (1.3%) | 2 (2.7%) | 0 | 3 (1.2%) | ||
PS_0 | 34 (64.2%) | 45 (57.0%) | 40 (54.8%) | 31 (60.8%) | 150 (58.6%) | V=0.07 (p=0.730) | |
PS_1 | 13 (24.5%) | 20 (25.3%) | 22 (30.1%) | 13 (25.5%) | 68 (26.6%) | V=0.05 (p=0.877) | |
PS_2 | 4 (7.5%) | 8 (10.1%) | 8 (11.0%) | 5 (9.8%) | 25 (9.8%) | V=0.04 (p=0.935) | |
PS_3 | 2 (3.8%) | 5 (6.3%) | 1 (1.4%) | 2 (3.9%) | 10 (3.9%) | V=0.10 (p=0.477) | |
PS_4 | 0 | 1 (1.3%) | 2 (2.7%) | 0 | 3 (1.2%) | V=0.10 (p=0.425) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||||
Factor | Detalis | NAFLD | Other | Total | Statistics |
Diagnosis | 55 (21.0%) | 207 (79.0%) | 262 | ||
Gender | F | 9 (16.4%) | 36 (17.4%) | 45 (17.2%) | OR=0.93 [0.42, 2.07] (p=1.000) |
M | 46 (83.6%) | 171 (82.6%) | 217 (82.8%) | ||
Age | μ ±DS | 70.83 ±7.01 | 66.35 ±9.1 | 67.29 ±8.88 | MW: p=0.001 |
M (min:max) | 71.1 (50.9:86.1) | 66.7 (45.2:86) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2014.87 ±3.23 | 2014.71 ±2.93 | 2014.75 ±2.99 | MW: p=0.608 |
M (min:max) | 2015 (2008:2019) | 2015 (2008:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 21.93 ±23.9 | 24.18 ±22.0 | 23.70 ±22.4 | MW: p=0.369 |
M (min:max) | 14 (0:110) | 19 (0:114) | 17 (0:114) | ||
Status | 0 | 22 (40.7%) | 61 (30.8%) | 83 (32.9%) | V=0.10 (p=0.263) |
1 | 29 (53.7%) | 130 (65.7%) | 159 (63.1%) | ||
2 | 3 (5.6%) | 7 (3.5%) | 10 (4.0%) | ||
MRI_diagnosis | 18 (32.7%) | 67 (32.5%) | 85 (32.6%) | OR=1.01 [0.54, 1.90] (p=1.000) | |
CT_Diagnosis | 33 (60.0%) | 120 (58.3%) | 153 (58.6%) | OR=1.07 [0.59, 1.97] (p=0.878) | |
US_Diagnosis | 20 (36.4%) | 67 (32.5%) | 87 (33.3%) | OR=1.19 [0.64, 2.21] (p=0.630) | |
HCC_Screening_18months_before | 23 (41.8%) | 74 (36.1%) | 97 (37.3%) | OR=1.27 [0.69, 2.33] (p=0.437) | |
US_Screening | 17 (30.9%) | 51 (30.0%) | 68 (30.2%) | OR=1.04 [0.54, 2.02] (p=1.000) | |
MRI_Screening | 6 (10.9%) | 16 (9.4%) | 22 (9.8%) | OR=1.18 [0.44, 3.18] (p=0.795) | |
CT_Screening | 9 (16.4%) | 30 (17.6%) | 39 (17.3%) | OR=0.91 [0.40, 2.06] (p=1.000) | |
ASH | 0 | 130 (62.8%) | 130 (49.6%) | OR=0.01 [0.00, 0.09] (p<0.001) | |
NAFLD | 55 (100%) | 51 (24.6%) | 106 (40.5%) | OR=337.31 [20.47, 5 558.13] (p<0.001) | |
Cirrhosis | 42 (76.4%) | 176 (85.0%) | 218 (83.2%) | OR=0.57 [0.27, 1.18] (p=0.155) | |
HCV | 0 | 57 (27.5%) | 57 (21.8%) | OR=0.02 [0.00, 0.39] (p<0.001) | |
HBc | 0 | 20 (9.7%) | 20 (7.6%) | OR=0.08 [0.00, 1.38] (p=0.010) | |
Diabetes | 35 (63.6%) | 63 (30.4%) | 98 (37.4%) | OR=4.00 [2.14, 7.47] (p<0.001) | |
Hipertension | 35 (68.6%) | 99 (49.5%) | 134 (53.4%) | OR=2.23 [1.16, 4.29] (p=0.018) | |
Hiperlipidemia | 16 (31.4%) | 27 (13.5%) | 43 (17.1%) | OR=2.93 [1.43, 6.00] (p=0.006) | |
Smoking | 0 | 38 (70.4%) | 97 (48.3%) | 135 (52.9%) | V=0.20 (p=0.007) |
1 | 16 (29.6%) | 90 (44.8%) | 106 (41.6%) | ||
2 | 0 | 14 (7.0%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 47 (87.0%) | 115 (57.2%) | 162 (63.5%) | V=0.26 (p<0.001) |
1 | 7 (13.0%) | 69 (34.3%) | 76 (29.8%) | ||
2 | 0 | 17 (8.5%) | 17 (6.7%) | ||
BMI | μ ±DS | 30.61 ±4.98 | 27.25 ±5.18 | 27.98 ±5.31 | MW: p<0.001 |
M (min:max) | 30.44 (18.48:42.17) | 26.46 (16.02:48.32) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 51 (96.2%) | 188 (94.5%) | 239 (94.8%) | OR=1.49 [0.32, 6.95] (p=1.000) |
2-3 | 2 (3.8%) | 11 (5.5%) | 13 (5.2%) | ||
Ascites (acc. to CP score) | 1 | 44 (84.6%) | 159 (79.9%) | 203 (80.9%) | V=0.10 (p=0.252) |
2 | 7 (13.5%) | 23 (11.6%) | 30 (12.0%) | ||
3 | 1 (1.9%) | 17 (8.5%) | 18 (7.2%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.88 ±18.2 | 24.69 ±39.7 | 24.54 ±36.5 | MW: p=0.154 |
M (min:max) | 18 (5:104) | 16 (3:413) | 16 (3:413) | ||
INR | μ ±DS | 1.16 ±0.162 | 1.16 ±0.195 | 1.16 ±0.188 | MW: p=0.806 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 33.01 ±4.59 | 32.68 ±6.06 | 32.75 ±5.78 | MW: p=0.961 |
M (min:max) | 33 (24:42) | 34 (17:49.8) | 33.5 (17:49.8) | ||
CHILD | 1 | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | V=0.02 (p=0.927) |
2 | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | ||
3 | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | ||
CHILD_A | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | OR=1.01 [0.52, 1.95] (p=1.000) | |
CHILD_B | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | OR=1.05 [0.53, 2.08] (p=0.863) | |
CHILD_C | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | OR=0.74 [0.16, 3.47] (p=1.000) | |
BCLC | 0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | V=0.06 (p=0.898) |
1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | ||
2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | ||
3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | ||
4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | ||
BCLC_0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | OR=0.53 [0.12, 2.41] (p=0.536) | |
BCLC_1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | OR=1.12 [0.60, 2.07] (p=0.753) | |
BCLC_2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | OR=0.96 [0.49, 1.88] (p=1.000) | |
BCLC_3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | OR=1.17 [0.58, 2.38] (p=0.712) | |
BCLC_4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | OR=0.75 [0.21, 2.70] (p=1.000) | |
Resection | 12 (21.8%) | 40 (19.4%) | 52 (19.9%) | OR=1.16 [0.56, 2.40] (p=0.706) | |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | OR=0.17 [0.01, 2.91] (p=0.126) | |
TACE | 7 (12.7%) | 30 (14.6%) | 37 (14.2%) | OR=0.85 [0.35, 2.06] (p=0.830) | |
TAE | 5 (9.1%) | 14 (6.9%) | 19 (7.3%) | OR=1.36 [0.47, 3.95] (p=0.565) | |
RFA | 2 (3.7%) | 6 (2.9%) | 8 (3.1%) | OR=1.28 [0.25, 6.51] (p=0.674) | |
MWA | 11 (20.0%) | 39 (19.0%) | 50 (19.2%) | OR=1.06 [0.50, 2.25] (p=0.849) | |
SIRT | 1 (1.8%) | 8 (3.9%) | 9 (3.5%) | OR=0.46 [0.06, 3.73] (p=0.689) | |
Sistemic_therapy | 12 (21.8%) | 43 (21.0%) | 55 (21.2%) | OR=1.05 [0.51, 2.17] (p=0.855) | |
Curative_treatment | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | OR=1.54 [0.84, 2.81] (p=0.162) | |
Loco_regional_therapies | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | OR=0.94 [0.46, 1.92] (p=1.000) | |
No_treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | OR=0.62 [0.24, 1.55] (p=0.401) | |
Treatment | Curative | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | V=0.14 (p=0.299) |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | ||
Loco-regional | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | ||
Systemic | 12 (21.8%) | 42 (20.5%) | 54 (20.8%) | ||
No treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | ||
Performance Status | 0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | V=0.08 (p=0.812) |
1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | ||
2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | ||
3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | ||
4 | 0 | 3 (1.5%) | 3 (1.2%) | ||
PS_0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | OR=1.34 [0.72, 2.51] (p=0.434) | |
PS_1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | OR=0.87 [0.44, 1.76] (p=0.861) | |
PS_2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | OR=0.71 [0.23, 2.16] (p=0.795) | |
PS_3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | OR=0.96 [0.20, 4.64] (p=1.000) | |
PS_4 | 0 | 3 (1.5%) | 3 (1.2%) | OR=0.54 [0.03, 10.52] (p=1.000) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | ASH | Other | Total | Statistics |
Diagnosis | 55 (21.0%) | 207 (79.0%) | 262 | ||
Gender | F | 9 (16.4%) | 36 (17.4%) | 45 (17.2%) | OR=0.93 [0.42, 2.07] (p=1.000) |
M | 46 (83.6%) | 171 (82.6%) | 217 (82.8%) | ||
Age | μ ±DS | 70.83 ±7.01 | 66.35 ±9.1 | 67.29 ±8.88 | MW: p=0.001 |
M (min:max) | 71.1 (50.9:86.1) | 66.7 (45.2:86) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2014.87 ±3.23 | 2014.71 ±2.93 | 2014.75 ±2.99 | MW: p=0.608 |
M (min:max) | 2015 (2008:2019) | 2015 (2008:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 21.93 ±23.9 | 24.18 ±22.0 | 23.70 ±22.4 | MW: p=0.369 |
M (min:max) | 14 (0:110) | 19 (0:114) | 17 (0:114) | ||
Status | 0 | 22 (40.7%) | 61 (30.8%) | 83 (32.9%) | V=0.10 (p=0.263) |
1 | 29 (53.7%) | 130 (65.7%) | 159 (63.1%) | ||
2 | 3 (5.6%) | 7 (3.5%) | 10 (4.0%) | ||
MRI_diagnosis | 18 (32.7%) | 67 (32.5%) | 85 (32.6%) | OR=1.01 [0.54, 1.90] (p=1.000) | |
CT_Diagnosis | 33 (60.0%) | 120 (58.3%) | 153 (58.6%) | OR=1.07 [0.59, 1.97] (p=0.878) | |
US_Diagnosis | 20 (36.4%) | 67 (32.5%) | 87 (33.3%) | OR=1.19 [0.64, 2.21] (p=0.630) | |
HCC_Screening_18months_before | 23 (41.8%) | 74 (36.1%) | 97 (37.3%) | OR=1.27 [0.69, 2.33] (p=0.437) | |
US_Screening | 17 (30.9%) | 51 (30.0%) | 68 (30.2%) | OR=1.04 [0.54, 2.02] (p=1.000) | |
MRI_Screening | 6 (10.9%) | 16 (9.4%) | 22 (9.8%) | OR=1.18 [0.44, 3.18] (p=0.795) | |
CT_Screening | 9 (16.4%) | 30 (17.6%) | 39 (17.3%) | OR=0.91 [0.40, 2.06] (p=1.000) | |
ASH | 0 | 130 (62.8%) | 130 (49.6%) | OR=0.01 [0.00, 0.09] (p<0.001) | |
NAFLD | 55 (100%) | 51 (24.6%) | 106 (40.5%) | OR=337.31 [20.47, 5 558.13] (p<0.001) | |
Cirrhosis | 42 (76.4%) | 176 (85.0%) | 218 (83.2%) | OR=0.57 [0.27, 1.18] (p=0.155) | |
HCV | 0 | 57 (27.5%) | 57 (21.8%) | OR=0.02 [0.00, 0.39] (p<0.001) | |
HBc | 0 | 20 (9.7%) | 20 (7.6%) | OR=0.08 [0.00, 1.38] (p=0.010) | |
Diabetes | 35 (63.6%) | 63 (30.4%) | 98 (37.4%) | OR=4.00 [2.14, 7.47] (p<0.001) | |
Hipertension | 35 (68.6%) | 99 (49.5%) | 134 (53.4%) | OR=2.23 [1.16, 4.29] (p=0.018) | |
Hiperlipidemia | 16 (31.4%) | 27 (13.5%) | 43 (17.1%) | OR=2.93 [1.43, 6.00] (p=0.006) | |
Smoking | 0 | 38 (70.4%) | 97 (48.3%) | 135 (52.9%) | V=0.20 (p=0.007) |
1 | 16 (29.6%) | 90 (44.8%) | 106 (41.6%) | ||
2 | 0 | 14 (7.0%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 47 (87.0%) | 115 (57.2%) | 162 (63.5%) | V=0.26 (p<0.001) |
1 | 7 (13.0%) | 69 (34.3%) | 76 (29.8%) | ||
2 | 0 | 17 (8.5%) | 17 (6.7%) | ||
BMI | μ ±DS | 30.61 ±4.98 | 27.25 ±5.18 | 27.98 ±5.31 | MW: p<0.001 |
M (min:max) | 30.44 (18.48:42.17) | 26.46 (16.02:48.32) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 51 (96.2%) | 188 (94.5%) | 239 (94.8%) | OR=1.49 [0.32, 6.95] (p=1.000) |
2-3 | 2 (3.8%) | 11 (5.5%) | 13 (5.2%) | ||
Ascites (acc. to CP score) | 1 | 44 (84.6%) | 159 (79.9%) | 203 (80.9%) | V=0.10 (p=0.252) |
2 | 7 (13.5%) | 23 (11.6%) | 30 (12.0%) | ||
3 | 1 (1.9%) | 17 (8.5%) | 18 (7.2%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.88 ±18.2 | 24.69 ±39.7 | 24.54 ±36.5 | MW: p=0.154 |
M (min:max) | 18 (5:104) | 16 (3:413) | 16 (3:413) | ||
INR | μ ±DS | 1.16 ±0.162 | 1.16 ±0.195 | 1.16 ±0.188 | MW: p=0.806 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 33.01 ±4.59 | 32.68 ±6.06 | 32.75 ±5.78 | MW: p=0.961 |
M (min:max) | 33 (24:42) | 34 (17:49.8) | 33.5 (17:49.8) | ||
CHILD | 1 | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | V=0.02 (p=0.927) |
2 | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | ||
3 | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | ||
CHILD_A | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | OR=1.01 [0.52, 1.95] (p=1.000) | |
CHILD_B | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | OR=1.05 [0.53, 2.08] (p=0.863) | |
CHILD_C | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | OR=0.74 [0.16, 3.47] (p=1.000) | |
BCLC | 0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | V=0.06 (p=0.898) |
1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | ||
2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | ||
3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | ||
4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | ||
BCLC_0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | OR=0.53 [0.12, 2.41] (p=0.536) | |
BCLC_1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | OR=1.12 [0.60, 2.07] (p=0.753) | |
BCLC_2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | OR=0.96 [0.49, 1.88] (p=1.000) | |
BCLC_3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | OR=1.17 [0.58, 2.38] (p=0.712) | |
BCLC_4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | OR=0.75 [0.21, 2.70] (p=1.000) | |
Resection | 12 (21.8%) | 40 (19.4%) | 52 (19.9%) | OR=1.16 [0.56, 2.40] (p=0.706) | |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | OR=0.17 [0.01, 2.91] (p=0.126) | |
TACE | 7 (12.7%) | 30 (14.6%) | 37 (14.2%) | OR=0.85 [0.35, 2.06] (p=0.830) | |
TAE | 5 (9.1%) | 14 (6.9%) | 19 (7.3%) | OR=1.36 [0.47, 3.95] (p=0.565) | |
RFA | 2 (3.7%) | 6 (2.9%) | 8 (3.1%) | OR=1.28 [0.25, 6.51] (p=0.674) | |
MWA | 11 (20.0%) | 39 (19.0%) | 50 (19.2%) | OR=1.06 [0.50, 2.25] (p=0.849) | |
SIRT | 1 (1.8%) | 8 (3.9%) | 9 (3.5%) | OR=0.46 [0.06, 3.73] (p=0.689) | |
Sistemic_therapy | 12 (21.8%) | 43 (21.0%) | 55 (21.2%) | OR=1.05 [0.51, 2.17] (p=0.855) | |
Curative_treatment | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | OR=1.54 [0.84, 2.81] (p=0.162) | |
Loco_regional_therapies | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | OR=0.94 [0.46, 1.92] (p=1.000) | |
No_treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | OR=0.62 [0.24, 1.55] (p=0.401) | |
Treatment | Curative | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | V=0.14 (p=0.299) |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | ||
Loco-regional | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | ||
Systemic | 12 (21.8%) | 42 (20.5%) | 54 (20.8%) | ||
No treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | ||
Performance Status | 0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | V=0.08 (p=0.812) |
1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | ||
2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | ||
3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | ||
4 | 0 | 3 (1.5%) | 3 (1.2%) | ||
PS_0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | OR=1.34 [0.72, 2.51] (p=0.434) | |
PS_1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | OR=0.87 [0.44, 1.76] (p=0.861) | |
PS_2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | OR=0.71 [0.23, 2.16] (p=0.795) | |
PS_3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | OR=0.96 [0.20, 4.64] (p=1.000) | |
PS_4 | 0 | 3 (1.5%) | 3 (1.2%) | OR=0.54 [0.03, 10.52] (p=1.000) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | VIRAL | Other | Total | Statistics |
Diagnosis | 55 (21.0%) | 207 (79.0%) | 262 | ||
Gender | F | 9 (16.4%) | 36 (17.4%) | 45 (17.2%) | OR=0.93 [0.42, 2.07] (p=1.000) |
M | 46 (83.6%) | 171 (82.6%) | 217 (82.8%) | ||
Age | μ ±DS | 70.83 ±7.01 | 66.35 ±9.1 | 67.29 ±8.88 | MW: p=0.001 |
M (min:max) | 71.1 (50.9:86.1) | 66.7 (45.2:86) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2014.87 ±3.23 | 2014.71 ±2.93 | 2014.75 ±2.99 | MW: p=0.608 |
M (min:max) | 2015 (2008:2019) | 2015 (2008:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 21.93 ±23.9 | 24.18 ±22.0 | 23.70 ±22.4 | MW: p=0.369 |
M (min:max) | 14 (0:110) | 19 (0:114) | 17 (0:114) | ||
Status | 0 | 22 (40.7%) | 61 (30.8%) | 83 (32.9%) | V=0.10 (p=0.263) |
1 | 29 (53.7%) | 130 (65.7%) | 159 (63.1%) | ||
2 | 3 (5.6%) | 7 (3.5%) | 10 (4.0%) | ||
MRI_diagnosis | 18 (32.7%) | 67 (32.5%) | 85 (32.6%) | OR=1.01 [0.54, 1.90] (p=1.000) | |
CT_Diagnosis | 33 (60.0%) | 120 (58.3%) | 153 (58.6%) | OR=1.07 [0.59, 1.97] (p=0.878) | |
US_Diagnosis | 20 (36.4%) | 67 (32.5%) | 87 (33.3%) | OR=1.19 [0.64, 2.21] (p=0.630) | |
HCC_Screening_18months_before | 23 (41.8%) | 74 (36.1%) | 97 (37.3%) | OR=1.27 [0.69, 2.33] (p=0.437) | |
US_Screening | 17 (30.9%) | 51 (30.0%) | 68 (30.2%) | OR=1.04 [0.54, 2.02] (p=1.000) | |
MRI_Screening | 6 (10.9%) | 16 (9.4%) | 22 (9.8%) | OR=1.18 [0.44, 3.18] (p=0.795) | |
CT_Screening | 9 (16.4%) | 30 (17.6%) | 39 (17.3%) | OR=0.91 [0.40, 2.06] (p=1.000) | |
ASH | 0 | 130 (62.8%) | 130 (49.6%) | OR=0.01 [0.00, 0.09] (p<0.001) | |
NAFLD | 55 (100%) | 51 (24.6%) | 106 (40.5%) | OR=337.31 [20.47, 5 558.13] (p<0.001) | |
Cirrhosis | 42 (76.4%) | 176 (85.0%) | 218 (83.2%) | OR=0.57 [0.27, 1.18] (p=0.155) | |
HCV | 0 | 57 (27.5%) | 57 (21.8%) | OR=0.02 [0.00, 0.39] (p<0.001) | |
HBc | 0 | 20 (9.7%) | 20 (7.6%) | OR=0.08 [0.00, 1.38] (p=0.010) | |
Diabetes | 35 (63.6%) | 63 (30.4%) | 98 (37.4%) | OR=4.00 [2.14, 7.47] (p<0.001) | |
Hipertension | 35 (68.6%) | 99 (49.5%) | 134 (53.4%) | OR=2.23 [1.16, 4.29] (p=0.018) | |
Hiperlipidemia | 16 (31.4%) | 27 (13.5%) | 43 (17.1%) | OR=2.93 [1.43, 6.00] (p=0.006) | |
Smoking | 0 | 38 (70.4%) | 97 (48.3%) | 135 (52.9%) | V=0.20 (p=0.007) |
1 | 16 (29.6%) | 90 (44.8%) | 106 (41.6%) | ||
2 | 0 | 14 (7.0%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 47 (87.0%) | 115 (57.2%) | 162 (63.5%) | V=0.26 (p<0.001) |
1 | 7 (13.0%) | 69 (34.3%) | 76 (29.8%) | ||
2 | 0 | 17 (8.5%) | 17 (6.7%) | ||
BMI | μ ±DS | 30.61 ±4.98 | 27.25 ±5.18 | 27.98 ±5.31 | MW: p<0.001 |
M (min:max) | 30.44 (18.48:42.17) | 26.46 (16.02:48.32) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 51 (96.2%) | 188 (94.5%) | 239 (94.8%) | OR=1.49 [0.32, 6.95] (p=1.000) |
2-3 | 2 (3.8%) | 11 (5.5%) | 13 (5.2%) | ||
Ascites (acc. to CP score) | 1 | 44 (84.6%) | 159 (79.9%) | 203 (80.9%) | V=0.10 (p=0.252) |
2 | 7 (13.5%) | 23 (11.6%) | 30 (12.0%) | ||
3 | 1 (1.9%) | 17 (8.5%) | 18 (7.2%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.88 ±18.2 | 24.69 ±39.7 | 24.54 ±36.5 | MW: p=0.154 |
M (min:max) | 18 (5:104) | 16 (3:413) | 16 (3:413) | ||
INR | μ ±DS | 1.16 ±0.162 | 1.16 ±0.195 | 1.16 ±0.188 | MW: p=0.806 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 33.01 ±4.59 | 32.68 ±6.06 | 32.75 ±5.78 | MW: p=0.961 |
M (min:max) | 33 (24:42) | 34 (17:49.8) | 33.5 (17:49.8) | ||
CHILD | 1 | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | V=0.02 (p=0.927) |
2 | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | ||
3 | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | ||
CHILD_A | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | OR=1.01 [0.52, 1.95] (p=1.000) | |
CHILD_B | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | OR=1.05 [0.53, 2.08] (p=0.863) | |
CHILD_C | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | OR=0.74 [0.16, 3.47] (p=1.000) | |
BCLC | 0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | V=0.06 (p=0.898) |
1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | ||
2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | ||
3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | ||
4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | ||
BCLC_0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | OR=0.53 [0.12, 2.41] (p=0.536) | |
BCLC_1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | OR=1.12 [0.60, 2.07] (p=0.753) | |
BCLC_2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | OR=0.96 [0.49, 1.88] (p=1.000) | |
BCLC_3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | OR=1.17 [0.58, 2.38] (p=0.712) | |
BCLC_4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | OR=0.75 [0.21, 2.70] (p=1.000) | |
Resection | 12 (21.8%) | 40 (19.4%) | 52 (19.9%) | OR=1.16 [0.56, 2.40] (p=0.706) | |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | OR=0.17 [0.01, 2.91] (p=0.126) | |
TACE | 7 (12.7%) | 30 (14.6%) | 37 (14.2%) | OR=0.85 [0.35, 2.06] (p=0.830) | |
TAE | 5 (9.1%) | 14 (6.9%) | 19 (7.3%) | OR=1.36 [0.47, 3.95] (p=0.565) | |
RFA | 2 (3.7%) | 6 (2.9%) | 8 (3.1%) | OR=1.28 [0.25, 6.51] (p=0.674) | |
MWA | 11 (20.0%) | 39 (19.0%) | 50 (19.2%) | OR=1.06 [0.50, 2.25] (p=0.849) | |
SIRT | 1 (1.8%) | 8 (3.9%) | 9 (3.5%) | OR=0.46 [0.06, 3.73] (p=0.689) | |
Sistemic_therapy | 12 (21.8%) | 43 (21.0%) | 55 (21.2%) | OR=1.05 [0.51, 2.17] (p=0.855) | |
Curative_treatment | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | OR=1.54 [0.84, 2.81] (p=0.162) | |
Loco_regional_therapies | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | OR=0.94 [0.46, 1.92] (p=1.000) | |
No_treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | OR=0.62 [0.24, 1.55] (p=0.401) | |
Treatment | Curative | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | V=0.14 (p=0.299) |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | ||
Loco-regional | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | ||
Systemic | 12 (21.8%) | 42 (20.5%) | 54 (20.8%) | ||
No treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | ||
Performance Status | 0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | V=0.08 (p=0.812) |
1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | ||
2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | ||
3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | ||
4 | 0 | 3 (1.5%) | 3 (1.2%) | ||
PS_0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | OR=1.34 [0.72, 2.51] (p=0.434) | |
PS_1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | OR=0.87 [0.44, 1.76] (p=0.861) | |
PS_2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | OR=0.71 [0.23, 2.16] (p=0.795) | |
PS_3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | OR=0.96 [0.20, 4.64] (p=1.000) | |
PS_4 | 0 | 3 (1.5%) | 3 (1.2%) | OR=0.54 [0.03, 10.52] (p=1.000) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | ASH & NAFLD | Other | Total | Statistics |
Diagnosis | 55 (21.0%) | 207 (79.0%) | 262 | ||
Gender | F | 9 (16.4%) | 36 (17.4%) | 45 (17.2%) | OR=0.93 [0.42, 2.07] (p=1.000) |
M | 46 (83.6%) | 171 (82.6%) | 217 (82.8%) | ||
Age | μ ±DS | 70.83 ±7.01 | 66.35 ±9.1 | 67.29 ±8.88 | MW: p=0.001 |
M (min:max) | 71.1 (50.9:86.1) | 66.7 (45.2:86) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2014.87 ±3.23 | 2014.71 ±2.93 | 2014.75 ±2.99 | MW: p=0.608 |
M (min:max) | 2015 (2008:2019) | 2015 (2008:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 21.93 ±23.9 | 24.18 ±22.0 | 23.70 ±22.4 | MW: p=0.369 |
M (min:max) | 14 (0:110) | 19 (0:114) | 17 (0:114) | ||
Status | 0 | 22 (40.7%) | 61 (30.8%) | 83 (32.9%) | V=0.10 (p=0.263) |
1 | 29 (53.7%) | 130 (65.7%) | 159 (63.1%) | ||
2 | 3 (5.6%) | 7 (3.5%) | 10 (4.0%) | ||
MRI_diagnosis | 18 (32.7%) | 67 (32.5%) | 85 (32.6%) | OR=1.01 [0.54, 1.90] (p=1.000) | |
CT_Diagnosis | 33 (60.0%) | 120 (58.3%) | 153 (58.6%) | OR=1.07 [0.59, 1.97] (p=0.878) | |
US_Diagnosis | 20 (36.4%) | 67 (32.5%) | 87 (33.3%) | OR=1.19 [0.64, 2.21] (p=0.630) | |
HCC_Screening_18months_before | 23 (41.8%) | 74 (36.1%) | 97 (37.3%) | OR=1.27 [0.69, 2.33] (p=0.437) | |
US_Screening | 17 (30.9%) | 51 (30.0%) | 68 (30.2%) | OR=1.04 [0.54, 2.02] (p=1.000) | |
MRI_Screening | 6 (10.9%) | 16 (9.4%) | 22 (9.8%) | OR=1.18 [0.44, 3.18] (p=0.795) | |
CT_Screening | 9 (16.4%) | 30 (17.6%) | 39 (17.3%) | OR=0.91 [0.40, 2.06] (p=1.000) | |
ASH | 0 | 130 (62.8%) | 130 (49.6%) | OR=0.01 [0.00, 0.09] (p<0.001) | |
NAFLD | 55 (100%) | 51 (24.6%) | 106 (40.5%) | OR=337.31 [20.47, 5 558.13] (p<0.001) | |
Cirrhosis | 42 (76.4%) | 176 (85.0%) | 218 (83.2%) | OR=0.57 [0.27, 1.18] (p=0.155) | |
HCV | 0 | 57 (27.5%) | 57 (21.8%) | OR=0.02 [0.00, 0.39] (p<0.001) | |
HBc | 0 | 20 (9.7%) | 20 (7.6%) | OR=0.08 [0.00, 1.38] (p=0.010) | |
Diabetes | 35 (63.6%) | 63 (30.4%) | 98 (37.4%) | OR=4.00 [2.14, 7.47] (p<0.001) | |
Hipertension | 35 (68.6%) | 99 (49.5%) | 134 (53.4%) | OR=2.23 [1.16, 4.29] (p=0.018) | |
Hiperlipidemia | 16 (31.4%) | 27 (13.5%) | 43 (17.1%) | OR=2.93 [1.43, 6.00] (p=0.006) | |
Smoking | 0 | 38 (70.4%) | 97 (48.3%) | 135 (52.9%) | V=0.20 (p=0.007) |
1 | 16 (29.6%) | 90 (44.8%) | 106 (41.6%) | ||
2 | 0 | 14 (7.0%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 47 (87.0%) | 115 (57.2%) | 162 (63.5%) | V=0.26 (p<0.001) |
1 | 7 (13.0%) | 69 (34.3%) | 76 (29.8%) | ||
2 | 0 | 17 (8.5%) | 17 (6.7%) | ||
BMI | μ ±DS | 30.61 ±4.98 | 27.25 ±5.18 | 27.98 ±5.31 | MW: p<0.001 |
M (min:max) | 30.44 (18.48:42.17) | 26.46 (16.02:48.32) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 51 (96.2%) | 188 (94.5%) | 239 (94.8%) | OR=1.49 [0.32, 6.95] (p=1.000) |
2-3 | 2 (3.8%) | 11 (5.5%) | 13 (5.2%) | ||
Ascites (acc. to CP score) | 1 | 44 (84.6%) | 159 (79.9%) | 203 (80.9%) | V=0.10 (p=0.252) |
2 | 7 (13.5%) | 23 (11.6%) | 30 (12.0%) | ||
3 | 1 (1.9%) | 17 (8.5%) | 18 (7.2%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.88 ±18.2 | 24.69 ±39.7 | 24.54 ±36.5 | MW: p=0.154 |
M (min:max) | 18 (5:104) | 16 (3:413) | 16 (3:413) | ||
INR | μ ±DS | 1.16 ±0.162 | 1.16 ±0.195 | 1.16 ±0.188 | MW: p=0.806 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 33.01 ±4.59 | 32.68 ±6.06 | 32.75 ±5.78 | MW: p=0.961 |
M (min:max) | 33 (24:42) | 34 (17:49.8) | 33.5 (17:49.8) | ||
CHILD | 1 | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | V=0.02 (p=0.927) |
2 | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | ||
3 | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | ||
CHILD_A | 31 (64.6%) | 128 (64.3%) | 159 (64.4%) | OR=1.01 [0.52, 1.95] (p=1.000) | |
CHILD_B | 15 (31.2%) | 60 (30.2%) | 75 (30.4%) | OR=1.05 [0.53, 2.08] (p=0.863) | |
CHILD_C | 2 (4.2%) | 11 (5.5%) | 13 (5.3%) | OR=0.74 [0.16, 3.47] (p=1.000) | |
BCLC | 0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | V=0.06 (p=0.898) |
1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | ||
2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | ||
3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | ||
4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | ||
BCLC_0 | 2 (3.7%) | 14 (6.8%) | 16 (6.1%) | OR=0.53 [0.12, 2.41] (p=0.536) | |
BCLC_1 | 21 (38.9%) | 75 (36.2%) | 96 (36.8%) | OR=1.12 [0.60, 2.07] (p=0.753) | |
BCLC_2 | 15 (27.8%) | 59 (28.5%) | 74 (28.4%) | OR=0.96 [0.49, 1.88] (p=1.000) | |
BCLC_3 | 13 (24.1%) | 44 (21.3%) | 57 (21.8%) | OR=1.17 [0.58, 2.38] (p=0.712) | |
BCLC_4 | 3 (5.6%) | 15 (7.2%) | 18 (6.9%) | OR=0.75 [0.21, 2.70] (p=1.000) | |
Resection | 12 (21.8%) | 40 (19.4%) | 52 (19.9%) | OR=1.16 [0.56, 2.40] (p=0.706) | |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | OR=0.17 [0.01, 2.91] (p=0.126) | |
TACE | 7 (12.7%) | 30 (14.6%) | 37 (14.2%) | OR=0.85 [0.35, 2.06] (p=0.830) | |
TAE | 5 (9.1%) | 14 (6.9%) | 19 (7.3%) | OR=1.36 [0.47, 3.95] (p=0.565) | |
RFA | 2 (3.7%) | 6 (2.9%) | 8 (3.1%) | OR=1.28 [0.25, 6.51] (p=0.674) | |
MWA | 11 (20.0%) | 39 (19.0%) | 50 (19.2%) | OR=1.06 [0.50, 2.25] (p=0.849) | |
SIRT | 1 (1.8%) | 8 (3.9%) | 9 (3.5%) | OR=0.46 [0.06, 3.73] (p=0.689) | |
Sistemic_therapy | 12 (21.8%) | 43 (21.0%) | 55 (21.2%) | OR=1.05 [0.51, 2.17] (p=0.855) | |
Curative_treatment | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | OR=1.54 [0.84, 2.81] (p=0.162) | |
Loco_regional_therapies | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | OR=0.94 [0.46, 1.92] (p=1.000) | |
No_treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | OR=0.62 [0.24, 1.55] (p=0.401) | |
Treatment | Curative | 25 (45.5%) | 72 (35.1%) | 97 (37.3%) | V=0.14 (p=0.299) |
Transplant | 0 | 10 (4.9%) | 10 (3.8%) | ||
Loco-regional | 12 (21.8%) | 47 (22.9%) | 59 (22.7%) | ||
Systemic | 12 (21.8%) | 42 (20.5%) | 54 (20.8%) | ||
No treatment | 6 (10.9%) | 34 (16.6%) | 40 (15.4%) | ||
Performance Status | 0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | V=0.08 (p=0.812) |
1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | ||
2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | ||
3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | ||
4 | 0 | 3 (1.5%) | 3 (1.2%) | ||
PS_0 | 34 (64.2%) | 116 (57.1%) | 150 (58.6%) | OR=1.34 [0.72, 2.51] (p=0.434) | |
PS_1 | 13 (24.5%) | 55 (27.1%) | 68 (26.6%) | OR=0.87 [0.44, 1.76] (p=0.861) | |
PS_2 | 4 (7.5%) | 21 (10.3%) | 25 (9.8%) | OR=0.71 [0.23, 2.16] (p=0.795) | |
PS_3 | 2 (3.8%) | 8 (3.9%) | 10 (3.9%) | OR=0.96 [0.20, 4.64] (p=1.000) | |
PS_4 | 0 | 3 (1.5%) | 3 (1.2%) | OR=0.54 [0.03, 10.52] (p=1.000) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
0.1.1 Year
Chi-squared Test for Trend in Proportionsdata: t\(NAFLD out of t\)total , using scores: 1 2 3 4 5 6 7 8 9 10 11 12 X-squared = 0.1, df = 1, p-value = 0.7
Cochran-Armitage test for trenddata: rbind(t\(NAFLD, t\)not NAFLD) Z = 0.4, dim = 12, p-value = 0.7 alternative hypothesis: two.sided
Jonckheere-Terpstrata testdata: db\(Year_of_diagnosis and db\)NAFLD Jonckheere z-value = 11, p-value <0.0000000000000002 alternative hypothesis: monotonic
Chi-squared Test for Trend in Proportionsdata: t\(ASH out of t\)total , using scores: 1 2 3 4 5 6 7 8 9 10 11 12 X-squared = 1, df = 1, p-value = 0.3
Cochran-Armitage test for trenddata: rbind(t\(ASH, t\)not ASH) Z = 1, dim = 12, p-value = 0.3 alternative hypothesis: two.sided
Jonckheere-Terpstrata testdata: db\(Year_of_diagnosis and db\)ASH Jonckheere z-value = 12, p-value <0.0000000000000002 alternative hypothesis: monotonic
Chi-squared Test for Trend in Proportionsdata: t\(VIRAL out of t\)total , using scores: 1 2 3 4 5 6 7 8 9 10 11 12 X-squared = 3, df = 1, p-value = 0.1
Cochran-Armitage test for trenddata: rbind(t\(VIRAL, t\)not VIRAL) Z = -2, dim = 12, p-value = 0.1 alternative hypothesis: two.sided
Jonckheere-Terpstrata testdata: db\(Year_of_diagnosis and db\)VIRAL Jonckheere z-value = 12, p-value <0.0000000000000002 alternative hypothesis: monotonic
Chi-squared Test for Trend in Proportionsdata: t\(`ASH & NAFLD` out of t\)total , using scores: 1 2 3 4 5 6 7 8 9 10 11 12 X-squared = 0.09, df = 1, p-value = 0.8
Cochran-Armitage test for trenddata: rbind(t\(`ASH & NAFLD`, t\)not ASH & NAFLD) Z = 0.8, dim = 12, p-value = 0.4 alternative hypothesis: two.sided
Jonckheere-Terpstrata testdata: db\(Year_of_diagnosis and db\)ASH & NAFLD Jonckheere z-value = 10, p-value <0.0000000000000002 alternative hypothesis: monotonic
0.2 Cox
| LR Chisq | Df | Pr(>Chisq) | |
|---|---|---|---|
| Treatment | 22.428 | 4 | 0.000 |
| Diagnosis | 8.006 | 3 | 0.046 |
| Age | 0.009 | 1 | 0.926 |
| Gender | 0.454 | 1 | 0.500 |
| Diabetes | 0.054 | 1 | 0.816 |
| Hipertension | 0.425 | 1 | 0.515 |
| Hiperlipidemia | 0.178 | 1 | 0.673 |
| Smoking | 8.710 | 2 | 0.013 |
| Alcohol_Consume | 7.182 | 2 | 0.028 |
| BMI | 5.000 | 1 | 0.025 |
| Bilirubin.total..µmol.L. | 12.578 | 1 | 0.000 |
| INR | 3.525 | 1 | 0.060 |
| Albumin..g.L. | 0.248 | 1 | 0.619 |
| BCLC | 8.830 | 4 | 0.066 |
| CHILD | 0.938 | 2 | 0.626 |
| Encephalopathy..according.to.Child.Pugh.score. | 1.047 | 1 | 0.306 |
| Ascites..according.to.Child.Pugh.score. | 10.116 | 2 | 0.006 |
| Performance.Status | 3.453 | 4 | 0.485 |
0.3 Univariate:
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 74 8 0.906 0.0317 0.846 0.970
36 30 23 0.577 0.0588 0.473 0.705
60 11 7 0.385 0.0730 0.265 0.558
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 2 0.800 0.126 0.587 1.000
36 3 3 0.429 0.174 0.193 0.951
60 3 0 0.429 0.174 0.193 0.951
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 48 4 0.925 0.0359 0.8576 0.999
36 14 29 0.305 0.0679 0.1975 0.472
60 4 9 0.094 0.0443 0.0373 0.237
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 21 24 0.514 0.0728 0.3892 0.678
36 8 8 0.284 0.0730 0.1721 0.470
60 3 3 0.163 0.0676 0.0719 0.367
Treatment=No treatment
time n.risk n.event survival std.err
12.0000 5.0000 26.0000 0.1993 0.0719
lower 95% CI upper 95% CI
0.0983 0.4041 
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional
Transplant 0.741 - -
Loco-regional 0.004 0.163 -
Systemic 0.00001855908714 0.059 0.121
No treatment < 0.0000000000000002 0.00016379859252 0.00000000000002
Systemic
Transplant -
Loco-regional -
Systemic -
No treatment 0.00000936564524
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Diagnosis=NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 29 11 0.772 0.0609 0.6617 0.901
36 10 13 0.388 0.0826 0.2560 0.589
60 4 5 0.175 0.0744 0.0759 0.403
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 45 21 0.698 0.0555 0.597 0.816
36 17 15 0.406 0.0667 0.294 0.561
60 8 7 0.221 0.0635 0.126 0.388
Diagnosis=VIRAL
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 51 18 0.741 0.0526 0.644 0.851
36 16 22 0.367 0.0632 0.262 0.514
60 5 5 0.205 0.0664 0.109 0.387
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 32 15 0.687 0.0672 0.567 0.832
36 12 18 0.263 0.0672 0.159 0.434
60 4 2 0.203 0.0642 0.109 0.377
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
NAFLD ASH VIRAL
ASH 1.0 - -
VIRAL 0.9 0.9 -
ASH & NAFLD 0.9 0.9 0.9
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Gender=F
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 29 12 0.703 0.0722 0.574 0.859
36 7 10 0.349 0.0881 0.213 0.572
60 4 1 0.279 0.0942 0.144 0.541
Gender=M
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 128 53 0.729 0.0320 0.669 0.795
36 48 58 0.358 0.0381 0.290 0.441
60 17 18 0.192 0.0357 0.133 0.276
Pairwise comparisons using Log-Rank test
data: db and Gender
F
M 0.6
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Diabetes=yes
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 56 27 0.706 0.0478 0.618 0.806
36 20 22 0.378 0.0582 0.280 0.512
60 7 8 0.194 0.0559 0.111 0.342
Diabetes=no
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 101 38 0.737 0.0368 0.668 0.813
36 35 46 0.345 0.0437 0.269 0.443
60 14 11 0.210 0.0420 0.142 0.311
Pairwise comparisons using Log-Rank test
data: db and Diabetes
yes
no 0.9
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Hipertension=yes
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 82 30 0.753 0.0393 0.680 0.835
36 29 33 0.392 0.0507 0.304 0.505
60 12 9 0.239 0.0509 0.157 0.363
Hipertension=no
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 73 34 0.691 0.0442 0.610 0.784
36 25 34 0.318 0.0486 0.236 0.429
60 9 9 0.177 0.0450 0.108 0.291
Pairwise comparisons using Log-Rank test
data: db and Hipertension
yes
no 0.3
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Hiperlipidemia=yes
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 22 9 0.771 0.0676 0.6490 0.915
36 7 11 0.351 0.0934 0.2081 0.591
60 3 3 0.180 0.0862 0.0708 0.460
Hiperlipidemia=no
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 133 55 0.715 0.0326 0.654 0.782
36 47 56 0.356 0.0381 0.289 0.439
60 18 15 0.213 0.0371 0.152 0.300
Pairwise comparisons using Log-Rank test
data: db and Hiperlipidemia
yes
no 0.8
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Smoking=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 95 27 0.784 0.0369 0.715 0.860
36 45 39 0.442 0.0462 0.360 0.543
60 19 16 0.255 0.0448 0.180 0.359
Smoking=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 49 33 0.641 0.0509 0.5485 0.749
36 6 20 0.241 0.0635 0.1436 0.404
60 2 3 0.100 0.0596 0.0313 0.321
Smoking=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 5 0.619 0.134 0.4045 0.947
36 3 5 0.181 0.114 0.0524 0.622
Pairwise comparisons using Log-Rank test
data: db and Smoking
0 1
1 0.004 -
2 0.145 0.903
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Alcohol_Consume=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 108 35 0.766 0.0348 0.700 0.837
36 45 45 0.411 0.0434 0.334 0.506
60 18 17 0.221 0.0414 0.153 0.319
Alcohol_Consume=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 33 25 0.615 0.0614 0.506 0.748
36 7 11 0.315 0.0756 0.197 0.504
60 3 2 0.225 0.0762 0.116 0.437
Alcohol_Consume=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 11 5 0.680 0.1189 0.4824 0.958
36 2 8 0.136 0.0892 0.0376 0.492
Pairwise comparisons using Log-Rank test
data: db and Alcohol_Consume
0 1
1 0.1 -
2 0.1 0.8
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
BCLC=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 13 1 0.938 0.0605 0.826 1.000
36 5 3 0.639 0.1498 0.404 1.000
60 3 2 0.384 0.1664 0.164 0.898
BCLC=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 70 12 0.856 0.0384 0.784 0.935
36 24 26 0.487 0.0597 0.383 0.619
60 8 5 0.326 0.0718 0.212 0.502
BCLC=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 50 11 0.829 0.0472 0.742 0.927
36 21 24 0.385 0.0659 0.275 0.539
60 8 9 0.194 0.0566 0.110 0.344
BCLC=3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 22 27 0.4887 0.0698 0.3693 0.647
36 5 13 0.1729 0.0587 0.0889 0.336
60 2 3 0.0692 0.0446 0.0196 0.245
BCLC=4
time n.risk n.event survival std.err
12.0000 1.0000 14.0000 0.1765 0.0925
lower 95% CI upper 95% CI
0.0632 0.4928 
Pairwise comparisons using Log-Rank test
data: db and BCLC
0 1 2 3
1 0.408 - - -
2 0.194 0.298 - -
3 0.004 0.00000601782821 0.00025609394761 -
4 0.00003035633346 0.00000000000001 0.00000000000230 0.00022454408338
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
CHILD=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 113 22 0.847 0.0302 0.790 0.908
36 44 42 0.472 0.0472 0.388 0.574
60 19 13 0.300 0.0489 0.218 0.413
CHILD=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 36 30 0.5665 0.0605 0.4595 0.698
36 9 21 0.1849 0.0517 0.1068 0.320
60 2 5 0.0599 0.0376 0.0175 0.205
CHILD=3
time n.risk n.event survival std.err
12.0000 3.0000 10.0000 0.2308 0.1169
lower 95% CI upper 95% CI
0.0855 0.6226 
Pairwise comparisons using Log-Rank test
data: db and CHILD
1 2
2 0.000000125007 -
3 0.000000000003 0.006
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Encephalopathy..according.to.Child.Pugh.score.=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 145 58 0.732 0.0303 0.675 0.794
36 53 58 0.384 0.0373 0.317 0.464
60 20 19 0.213 0.0363 0.152 0.297
Encephalopathy..according.to.Child.Pugh.score.=2-3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 6 6 0.5000 0.1443 0.2840 0.880
36 1 5 0.0833 0.0798 0.0128 0.544
60 1 0 0.0833 0.0798 0.0128 0.544
Pairwise comparisons using Log-Rank test
data: db and Encephalopathy..according.to.Child.Pugh.score.
1
2-3 0.005
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Ascites..according.to.Child.Pugh.score.=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 133 38 0.793 0.0300 0.736 0.854
36 50 54 0.416 0.0410 0.343 0.504
60 20 16 0.247 0.0411 0.178 0.342
Ascites..according.to.Child.Pugh.score.=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 11 16 0.410 0.0978 0.2570 0.655
36 3 4 0.219 0.0882 0.0993 0.482
Ascites..according.to.Child.Pugh.score.=3
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 7 10 0.4118 0.1194 0.2333 0.727
36 1 5 0.0784 0.0726 0.0128 0.482
60 1 0 0.0784 0.0726 0.0128 0.482
Pairwise comparisons using Log-Rank test
data: db and Ascites..according.to.Child.Pugh.score.
1 2
2 0.0000008 -
3 0.0002652 1
P value adjustment method: BH
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
make.names(by)))
Performance.Status=0
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 95 25 0.811 0.0343 0.746 0.881
36 37 32 0.483 0.0502 0.394 0.592
60 11 13 0.249 0.0548 0.162 0.383
Performance.Status=1
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 48 17 0.728 0.0564 0.625 0.847
36 15 26 0.292 0.0591 0.196 0.434
60 10 4 0.211 0.0549 0.127 0.351
Performance.Status=2
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 10 13 0.48 0.0999 0.3192 0.722
36 2 7 0.12 0.0753 0.0351 0.410
Performance.Status=3
time n.risk n.event survival std.err
12.0000 1.0000 8.0000 0.2000 0.1265
lower 95% CI upper 95% CI
0.0579 0.6908
Performance.Status=4
time n.risk n.event survival std.err lower 95% CI upper 95% CI
Pairwise comparisons using Log-Rank test
data: db and Performance.Status
0 1 2 3
1 0.237 - - -
2 0.0000081015 0.005 - -
3 0.0000000008 0.0000081015 0.074 -
4 0.0004677835 0.011 0.502 0.894
P value adjustment method: BH 0.4 Survival: Treatment x Diagnosis
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 74 8 0.906 0.0317 0.846 0.970
36 30 23 0.577 0.0588 0.473 0.705
60 11 7 0.385 0.0730 0.265 0.558
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 2 0.800 0.126 0.587 1.000
36 3 3 0.429 0.174 0.193 0.951
60 3 0 0.429 0.174 0.193 0.951
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 48 4 0.925 0.0359 0.8576 0.999
36 14 29 0.305 0.0679 0.1975 0.472
60 4 9 0.094 0.0443 0.0373 0.237
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 21 24 0.514 0.0728 0.3892 0.678
36 8 8 0.284 0.0730 0.1721 0.470
60 3 3 0.163 0.0676 0.0719 0.367
Treatment=No treatment
time n.risk n.event survival std.err
12.0000 5.0000 26.0000 0.1993 0.0719
lower 95% CI upper 95% CI
0.0983 0.4041 | records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment=Curative | 94 | 94 | 94 | 42 | 48.22 | 3.68 | 50 | 28 | 82 |
| Treatment=Transplant | 10 | 10 | 10 | 5 | 47.67 | 11.33 | 30 | 23 | NA |
| Treatment=Loco-regional | 57 | 57 | 57 | 43 | 32.69 | 2.91 | 29 | 24 | 33 |
| Treatment=Systemic | 53 | 53 | 53 | 37 | 26.24 | 4.15 | 13 | 9 | 32 |
| Treatment=No treatment | 35 | 35 | 35 | 31 | 6.79 | 1.56 | 3 | 2 | 7 |
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional
Transplant 0.741 - -
Loco-regional 0.004 0.163 -
Systemic 0.00001855908714 0.059 0.121
No treatment < 0.0000000000000002 0.00016379859252 0.00000000000002
Systemic
Transplant -
Loco-regional -
Systemic -
No treatment 0.00000936564524
P value adjustment method: BH
Pairwise comparisons using Log-Rank test
data: db2 and Treatment
Curative Loco-regional Systemic
Loco-regional 0.003 - -
Systemic 0.00001113545228 0.097 -
No treatment < 0.0000000000000002 0.00000000000001 0.00000561938714
P value adjustment method: BH 
0.4.1 Diagnosis == “ASH”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 21 2 0.913 0.0588 0.805 1.000
36 6 7 0.523 0.1176 0.336 0.812
60 3 1 0.418 0.1327 0.225 0.779
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 3 0 1 0 1 1
36 2 0 1 0 1 1
60 2 0 1 0 1 1
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 13 0 1.000 0.000 1.0000 1.000
36 4 7 0.417 0.142 0.2133 0.814
60 1 3 0.104 0.097 0.0168 0.646
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 7 0.521 0.132 0.3166 0.857
36 5 1 0.434 0.136 0.2351 0.801
60 2 3 0.174 0.110 0.0504 0.598
Treatment=No treatment
time n.risk n.event survival std.err lower 95% CI upper 95% CI| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment=Curative | 27 | 27 | 27 | 11 | 46.09 | 6.539 | 39.0 | 28 | NA |
| Treatment=Transplant | 3 | 3 | 3 | 0 | 76.00 | 0.000 | NA | NA | NA |
| Treatment=Loco-regional | 16 | 16 | 16 | 10 | 38.48 | 4.823 | 33.0 | 27 | NA |
| Treatment=Systemic | 16 | 16 | 16 | 12 | 28.49 | 6.742 | 13.0 | 7 | NA |
| Treatment=No treatment | 13 | 13 | 13 | 11 | 3.33 | 0.584 | 2.5 | 2 | NA |
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional Systemic
Transplant 0.20 - - -
Loco-regional 0.53 0.07 - -
Systemic 0.05 0.04 0.48 -
No treatment 0.00000000005 0.01 0.00000011027 0.00008204834
P value adjustment method: BH
Pairwise comparisons using Log-Rank test
data: db2 and Treatment
Curative Loco-regional Systemic
Loco-regional 0.53 - -
Systemic 0.04 0.52 -
No treatment 0.00000000003 0.00000006616 0.00004922900
P value adjustment method: BH 
0.4.2 Diagnosis == “NAFLD”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 18 1 0.955 0.0444 0.871 1.000
36 9 6 0.607 0.1174 0.415 0.887
60 4 4 0.308 0.1227 0.141 0.673
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 2 0.818 0.116 0.6192 1.000
36 1 5 0.184 0.153 0.0359 0.944
Treatment=Systemic
time n.risk n.event survival std.err
12.000 1.000 6.000 0.333 0.175
lower 95% CI upper 95% CI
0.119 0.932
Treatment=No treatment
time n.risk n.event survival std.err
12.000 2.000 2.000 0.625 0.213
lower 95% CI upper 95% CI
0.320 1.000 | records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment=Curative | 25 | 25 | 25 | 11 | 29.7 | 2.32 | 50.0 | 23 | NA |
| Treatment=Loco-regional | 11 | 11 | 11 | 8 | 21.2 | 3.54 | 17.0 | 14 | NA |
| Treatment=Systemic | 12 | 12 | 12 | 6 | 17.3 | 5.04 | 10.5 | 8 | NA |
| Treatment=No treatment | 6 | 6 | 6 | 4 | 12.8 | 4.09 | 16.0 | 3 | NA |
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Loco-regional Systemic
Loco-regional 0.02 - -
Systemic 0.01 0.35 -
No treatment 0.01 0.35 0.88
P value adjustment method: BH
Pairwise comparisons using Log-Rank test
data: db2 and Treatment
Curative Loco-regional Systemic
Loco-regional 0.02 - -
Systemic 0.01 0.35 -
No treatment 0.01 0.35 0.88
P value adjustment method: BH 
0.4.3 Diagnosis == “VIRAL”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 21 2 0.913 0.0588 0.805 1.000
36 6 7 0.523 0.1176 0.336 0.812
60 3 1 0.418 0.1327 0.225 0.779
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 3 0 1 0 1 1
36 2 0 1 0 1 1
60 2 0 1 0 1 1
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 13 0 1.000 0.000 1.0000 1.000
36 4 7 0.417 0.142 0.2133 0.814
60 1 3 0.104 0.097 0.0168 0.646
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 7 0.521 0.132 0.3166 0.857
36 5 1 0.434 0.136 0.2351 0.801
60 2 3 0.174 0.110 0.0504 0.598
Treatment=No treatment
time n.risk n.event survival std.err lower 95% CI upper 95% CI| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment=Curative | 27 | 27 | 27 | 11 | 46.09 | 6.539 | 39.0 | 28 | NA |
| Treatment=Transplant | 3 | 3 | 3 | 0 | 76.00 | 0.000 | NA | NA | NA |
| Treatment=Loco-regional | 16 | 16 | 16 | 10 | 38.48 | 4.823 | 33.0 | 27 | NA |
| Treatment=Systemic | 16 | 16 | 16 | 12 | 28.49 | 6.742 | 13.0 | 7 | NA |
| Treatment=No treatment | 13 | 13 | 13 | 11 | 3.33 | 0.584 | 2.5 | 2 | NA |
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional Systemic
Transplant 0.20 - - -
Loco-regional 0.53 0.07 - -
Systemic 0.05 0.04 0.48 -
No treatment 0.00000000005 0.01 0.00000011027 0.00008204834
P value adjustment method: BH
Pairwise comparisons using Log-Rank test
data: db2 and Treatment
Curative Loco-regional Systemic
Loco-regional 0.53 - -
Systemic 0.04 0.52 -
No treatment 0.00000000003 0.00000006616 0.00004922900
P value adjustment method: BH
0.4.4 Diagnosis == “ASH & NAFLD”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Treatment=Curative
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 4 0.692 0.128 0.482 0.995
36 4 3 0.404 0.149 0.196 0.831
60 1 0 0.404 0.149 0.196 0.831
Treatment=Transplant
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 2 0 1.0 0.000 1.000 1
36 1 1 0.5 0.354 0.125 1
60 1 0 0.5 0.354 0.125 1
Treatment=Loco-regional
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 10 2 0.8182 0.1163 0.619 1.000
36 4 6 0.2727 0.1343 0.104 0.716
60 1 2 0.0909 0.0867 0.014 0.589
Treatment=Systemic
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 4 0.733 0.114 0.5405 0.995
36 3 6 0.244 0.121 0.0924 0.647
60 1 0 0.244 0.121 0.0924 0.647
Treatment=No treatment
time n.risk n.event survival std.err
12.0000 2.0000 5.0000 0.2857 0.1707
lower 95% CI upper 95% CI
0.0886 0.9218 | records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Treatment=Curative | 14 | 14 | 14 | 7 | 38.56 | 8.80 | 24 | 11 | NA |
| Treatment=Transplant | 2 | 2 | 2 | 1 | 52.00 | 15.56 | 30 | 30 | NA |
| Treatment=Loco-regional | 12 | 12 | 12 | 10 | 28.82 | 5.53 | 27 | 17 | NA |
| Treatment=Systemic | 15 | 15 | 15 | 11 | 32.58 | 7.07 | 25 | 22 | NA |
| Treatment=No treatment | 7 | 7 | 7 | 7 | 6.57 | 3.59 | 2 | 0 | NA |
Pairwise comparisons using Log-Rank test
data: db and Treatment
Curative Transplant Loco-regional Systemic
Transplant 0.70 - - -
Loco-regional 0.69 0.50 - -
Systemic 0.80 0.50 0.81 -
No treatment 0.01 0.07 0.01 0.01
P value adjustment method: BH
Pairwise comparisons using Log-Rank test
data: db2 and Treatment
Curative Loco-regional Systemic
Loco-regional 0.723 - -
Systemic 0.808 0.808 -
No treatment 0.008 0.008 0.008
P value adjustment method: BH 
0.5 Survval: Diagnosis x Treatment
Factor | Detalis | Curative | Transplant | Loco-regional | Systemic | No treatment | Total | Statistics |
Treatment | 97 (37.3%) | 10 (3.8%) | 59 (22.7%) | 54 (20.8%) | 40 (15.4%) | 260 | ||
Gender | F | 23 (23.7%) | 2 (20.0%) | 7 (11.9%) | 4 (7.4%) | 9 (22.5%) | 45 (17.3%) | V=0.18 (p=0.075) |
M | 74 (76.3%) | 8 (80.0%) | 52 (88.1%) | 50 (92.6%) | 31 (77.5%) | 215 (82.7%) | ||
Age | μ ±DS | 68.02 ±8.55 | 59.15 ±7.34 | 69.32 ±8.74 | 67.11 ±9.33 | 65.11 ±8.41 | 67.29 ±8.88 | Kruskal-Wallis: p=0.004 |
M (min:max) | 70.2 (45.2:83.9) | 59.35 (48:70.5) | 70.5 (50.9:86) | 67.95 (48.3:86.1) | 65.3 (49.1:83.9) | 68.2 (45.2:86.1) | ||
Year of diagnosis | μ ±DS | 2015.37 ±2.73 | 2013.10 ±2.38 | 2013.21 ±3.12 | 2015.48 ±2.79 | 2014.80 ±2.97 | 2014.75 ±2.99 | Kruskal-Wallis: p<0.001 |
M (min:max) | 2016 (2009:2019) | 2012 (2011:2018) | 2012.5 (2008:2019) | 2016 (2009:2019) | 2015.5 (2010:2019) | 2015 (2008:2019) | ||
Survival | μ ±DS | 30.26 ±24.1 | 38.00 ±30.4 | 27.54 ±18.9 | 17.55 ±19.5 | 5.69 ±7.85 | 23.70 ±22.4 | Kruskal-Wallis: p<0.001 |
M (min:max) | 23 (1:114) | 24 (5:85) | 24 (2:93) | 9 (1:82) | 2 (0:32) | 17 (0:114) | ||
Status | 0 | 48 (50.5%) | 5 (50.0%) | 11 (19.3%) | 16 (29.6%) | 3 (8.6%) | 83 (33.1%) | V=0.25 (p<0.001) |
1 | 42 (44.2%) | 5 (50.0%) | 43 (75.4%) | 37 (68.5%) | 31 (88.6%) | 158 (62.9%) | ||
2 | 5 (5.3%) | 0 | 3 (5.3%) | 1 (1.9%) | 1 (2.9%) | 10 (4.0%) | ||
MRI_diagnosis | 38 (39.6%) | 2 (20.0%) | 20 (33.9%) | 8 (14.8%) | 17 (42.5%) | 85 (32.8%) | V=0.22 (p=0.015) | |
CT_Diagnosis | 47 (49.0%) | 5 (50.0%) | 34 (57.6%) | 39 (72.2%) | 27 (67.5%) | 152 (58.7%) | V=0.19 (p=0.051) | |
US_Diagnosis | 29 (30.2%) | 0 | 27 (45.8%) | 18 (33.3%) | 13 (32.5%) | 87 (33.6%) | V=0.19 (p=0.050) | |
HCC_Screening_18months_before | 50 (52.1%) | 4 (40.0%) | 23 (39.7%) | 11 (20.4%) | 8 (20.0%) | 96 (37.2%) | V=0.28 (p<0.001) | |
US_Screening | 39 (43.8%) | 2 (22.2%) | 14 (28.0%) | 6 (15.0%) | 7 (20.0%) | 68 (30.5%) | V=0.25 (p=0.007) | |
MRI_Screening | 12 (13.5%) | 1 (11.1%) | 7 (14.0%) | 0 | 2 (5.7%) | 22 (9.9%) | V=0.18 (p=0.119) | |
CT_Screening | 15 (16.9%) | 2 (22.2%) | 12 (24.0%) | 5 (12.5%) | 4 (11.4%) | 38 (17.0%) | V=0.12 (p=0.517) | |
ASH | 41 (42.3%) | 5 (50.0%) | 29 (49.2%) | 31 (57.4%) | 23 (57.5%) | 129 (49.6%) | V=0.13 (p=0.354) | |
NAFLD | 39 (40.2%) | 2 (20.0%) | 25 (42.4%) | 27 (50.0%) | 13 (32.5%) | 106 (40.8%) | V=0.14 (p=0.298) | |
Cirrhosis | 75 (77.3%) | 8 (80.0%) | 52 (88.1%) | 44 (81.5%) | 37 (92.5%) | 216 (83.1%) | V=0.15 (p=0.195) | |
HCV | 25 (25.8%) | 1 (10.0%) | 14 (23.7%) | 6 (11.1%) | 10 (25.0%) | 56 (21.5%) | V=0.15 (p=0.219) | |
HBc | 6 (6.2%) | 4 (40.0%) | 4 (6.8%) | 5 (9.3%) | 1 (2.5%) | 20 (7.7%) | V=0.25 (p=0.002) | |
Diagnosis | NAFLD | 25 (25.8%) | 0 | 12 (20.3%) | 12 (22.2%) | 6 (15.0%) | 55 (21.2%) | V=0.12 (p=0.431) |
ASH | 27 (27.8%) | 3 (30.0%) | 16 (27.1%) | 16 (29.6%) | 16 (40.0%) | 78 (30.0%) | ||
VIRAL | 31 (32.0%) | 5 (50.0%) | 18 (30.5%) | 11 (20.4%) | 11 (27.5%) | 76 (29.2%) | ||
ASH & NAFLD | 14 (14.4%) | 2 (20.0%) | 13 (22.0%) | 15 (27.8%) | 7 (17.5%) | 51 (19.6%) | ||
Diabetes | 39 (40.2%) | 2 (20.0%) | 18 (30.5%) | 21 (38.9%) | 18 (45.0%) | 98 (37.7%) | V=0.12 (p=0.429) | |
Hipertension | 50 (53.2%) | 5 (50.0%) | 34 (60.7%) | 32 (59.3%) | 13 (37.1%) | 134 (53.8%) | V=0.15 (p=0.222) | |
Hiperlipidemia | 18 (19.1%) | 1 (10.0%) | 8 (14.3%) | 13 (24.1%) | 3 (8.6%) | 43 (17.3%) | V=0.14 (p=0.336) | |
Smoking | 0 | 48 (52.2%) | 7 (70.0%) | 39 (67.2%) | 23 (43.4%) | 17 (42.5%) | 134 (53.0%) | V=0.14 (p=0.238) |
1 | 38 (41.3%) | 3 (30.0%) | 17 (29.3%) | 26 (49.1%) | 21 (52.5%) | 105 (41.5%) | ||
2 | 6 (6.5%) | 0 | 2 (3.4%) | 4 (7.5%) | 2 (5.0%) | 14 (5.5%) | ||
Alcohol_Consume | 0 | 57 (62.0%) | 8 (80.0%) | 43 (74.1%) | 31 (58.5%) | 22 (55.0%) | 161 (63.6%) | V=0.12 (p=0.473) |
1 | 30 (32.6%) | 1 (10.0%) | 11 (19.0%) | 18 (34.0%) | 15 (37.5%) | 75 (29.6%) | ||
2 | 5 (5.4%) | 1 (10.0%) | 4 (6.9%) | 4 (7.5%) | 3 (7.5%) | 17 (6.7%) | ||
BMI | μ ±DS | 28.14 ±5.15 | 25.40 ±5.8 | 27.72 ±5.84 | 28.52 ±5.11 | 27.89 ±5.15 | 27.98 ±5.31 | Kruskal-Wallis: p=0.654 |
M (min:max) | 27.52 (16.02:42.17) | 26.53 (16.25:35.79) | 26.57 (18.48:48.32) | 29.22 (18.52:46.02) | 27.38 (19.78:46.65) | 27.3 (16.02:48.32) | ||
Encephalopathy (acc. to CP score) | 1 | 89 (96.7%) | 9 (90.0%) | 55 (96.5%) | 52 (100%) | 33 (84.6%) | 238 (95.2%) | V=0.23 (p=0.009) |
2-3 | 3 (3.3%) | 1 (10.0%) | 2 (3.5%) | 0 | 6 (15.4%) | 12 (4.8%) | ||
Ascites (acc. to CP score) | 1 | 84 (91.3%) | 8 (80.0%) | 49 (87.5%) | 43 (82.7%) | 19 (48.7%) | 203 (81.5%) | V=0.32 (p<0.001) |
2 | 6 (6.5%) | 0 | 7 (12.5%) | 7 (13.5%) | 9 (23.1%) | 29 (11.6%) | ||
3 | 2 (2.2%) | 2 (20.0%) | 0 | 2 (3.8%) | 11 (28.2%) | 17 (6.8%) | ||
Bilirubin total (µmol/L) | μ ±DS | 17.33 ±13.5 | 21.20 ±17.6 | 19.98 ±13.5 | 26.62 ±55.7 | 46.50 ±56.0 | 24.54 ±36.5 | Kruskal-Wallis: p<0.001 |
M (min:max) | 13 (4:77) | 17 (5:52) | 17 (4:67) | 16 (3:413) | 28 (6:286) | 16 (3:413) | ||
INR | μ ±DS | 1.13 ±0.176 | 1.22 ±0.278 | 1.15 ±0.149 | 1.14 ±0.168 | 1.27 ±0.229 | 1.16 ±0.188 | Kruskal-Wallis: p<0.001 |
M (min:max) | 1.08 (0.8:1.96) | 1.29 (0.8:1.56) | 1.14 (0.99:1.64) | 1.1 (0.8:1.83) | 1.26 (1:2.07) | 1.12 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 35.01 ±4.68 | 33.10 ±5.9 | 33.63 ±5.58 | 32.62 ±5.34 | 26.74 ±4.41 | 32.75 ±5.78 | Kruskal-Wallis: p<0.001 |
M (min:max) | 35 (21:44) | 35 (24:40) | 34 (23:49.8) | 32.5 (17:41) | 26 (20:40) | 33.5 (17:49.8) | ||
CHILD | 1 | 71 (78.0%) | 7 (70.0%) | 42 (73.7%) | 32 (62.7%) | 7 (18.9%) | 159 (64.6%) | V=0.35 (p<0.001) |
2 | 18 (19.8%) | 2 (20.0%) | 15 (26.3%) | 18 (35.3%) | 21 (56.8%) | 74 (30.1%) | ||
3 | 2 (2.2%) | 1 (10.0%) | 0 | 1 (2.0%) | 9 (24.3%) | 13 (5.3%) | ||
CHILD_A | 71 (78.0%) | 7 (70.0%) | 42 (73.7%) | 32 (62.7%) | 7 (18.9%) | 159 (64.6%) | V=0.42 (p<0.001) | |
CHILD_B | 18 (19.8%) | 2 (20.0%) | 15 (26.3%) | 18 (35.3%) | 21 (56.8%) | 74 (30.1%) | V=0.28 (p<0.001) | |
CHILD_C | 2 (2.2%) | 1 (10.0%) | 0 | 1 (2.0%) | 9 (24.3%) | 13 (5.3%) | V=0.37 (p<0.001) | |
BCLC | 0 | 14 (14.6%) | 1 (10.0%) | 0 | 0 | 0 | 15 (5.8%) | V=0.40 (p<0.001) |
1 | 59 (61.5%) | 4 (40.0%) | 23 (39.0%) | 3 (5.6%) | 7 (17.5%) | 96 (37.1%) | ||
2 | 18 (18.8%) | 1 (10.0%) | 29 (49.2%) | 20 (37.0%) | 6 (15.0%) | 74 (28.6%) | ||
3 | 5 (5.2%) | 4 (40.0%) | 5 (8.5%) | 29 (53.7%) | 14 (35.0%) | 57 (22.0%) | ||
4 | 0 | 0 | 2 (3.4%) | 2 (3.7%) | 13 (32.5%) | 17 (6.6%) | ||
BCLC_0 | 14 (14.6%) | 1 (10.0%) | 0 | 0 | 0 | 15 (5.8%) | V=0.30 (p<0.001) | |
BCLC_1 | 59 (61.5%) | 4 (40.0%) | 23 (39.0%) | 3 (5.6%) | 7 (17.5%) | 96 (37.1%) | V=0.46 (p<0.001) | |
BCLC_2 | 18 (18.8%) | 1 (10.0%) | 29 (49.2%) | 20 (37.0%) | 6 (15.0%) | 74 (28.6%) | V=0.30 (p<0.001) | |
BCLC_3 | 5 (5.2%) | 4 (40.0%) | 5 (8.5%) | 29 (53.7%) | 14 (35.0%) | 57 (22.0%) | V=0.48 (p<0.001) | |
BCLC_4 | 0 | 0 | 2 (3.4%) | 2 (3.7%) | 13 (32.5%) | 17 (6.6%) | V=0.45 (p<0.001) | |
Resection | 51 (52.6%) | 1 (10.0%) | 0 | 0 | 0 | 52 (20.0%) | V=0.63 (p<0.001) | |
Transplant | 0 | 10 (100%) | 0 | 0 | 0 | 10 (3.8%) | V=1.00 (p<0.001) | |
TACE | 3 (3.1%) | 1 (10.0%) | 33 (55.9%) | 0 | 0 | 37 (14.2%) | V=0.65 (p<0.001) | |
TAE | 0 | 0 | 18 (30.5%) | 0 | 1 (2.5%) | 19 (7.3%) | V=0.48 (p<0.001) | |
RFA | 8 (8.2%) | 0 | 0 | 0 | 0 | 8 (3.1%) | V=0.23 (p=0.008) | |
MWA | 49 (50.5%) | 0 | 1 (1.7%) | 0 | 0 | 50 (19.2%) | V=0.61 (p<0.001) | |
SIRT | 1 (1.0%) | 0 | 8 (13.6%) | 0 | 0 | 9 (3.5%) | V=0.30 (p<0.001) | |
Sistemic_therapy | 0 | 1 (10.0%) | 0 | 54 (100%) | 0 | 55 (21.2%) | V=0.99 (p<0.001) | |
Curative_treatment | 97 (100%) | 0 | 0 | 0 | 0 | 97 (37.3%) | V=1.00 (p<0.001) | |
Loco_regional_therapies | 0 | 0 | 59 (100%) | 0 | 0 | 59 (22.7%) | V=1.00 (p<0.001) | |
No_treatment | 0 | 0 | 0 | 0 | 40 (100%) | 40 (15.4%) | V=1.00 (p<0.001) | |
Performance Status | 0 | 68 (73.9%) | 4 (40.0%) | 32 (54.2%) | 34 (64.2%) | 10 (25.0%) | 148 (58.3%) | V=0.27 (p<0.001) |
1 | 20 (21.7%) | 4 (40.0%) | 23 (39.0%) | 12 (22.6%) | 9 (22.5%) | 68 (26.8%) | ||
2 | 3 (3.3%) | 2 (20.0%) | 2 (3.4%) | 6 (11.3%) | 12 (30.0%) | 25 (9.8%) | ||
3 | 0 | 0 | 2 (3.4%) | 1 (1.9%) | 7 (17.5%) | 10 (3.9%) | ||
4 | 1 (1.1%) | 0 | 0 | 0 | 2 (5.0%) | 3 (1.2%) | ||
PS_0 | 68 (73.9%) | 4 (40.0%) | 32 (54.2%) | 34 (64.2%) | 10 (25.0%) | 148 (58.3%) | V=0.34 (p<0.001) | |
PS_1 | 20 (21.7%) | 4 (40.0%) | 23 (39.0%) | 12 (22.6%) | 9 (22.5%) | 68 (26.8%) | V=0.17 (p=0.116) | |
PS_2 | 3 (3.3%) | 2 (20.0%) | 2 (3.4%) | 6 (11.3%) | 12 (30.0%) | 25 (9.8%) | V=0.33 (p<0.001) | |
PS_3 | 0 | 0 | 2 (3.4%) | 1 (1.9%) | 7 (17.5%) | 10 (3.9%) | V=0.31 (p<0.001) | |
PS_4 | 1 (1.1%) | 0 | 0 | 0 | 2 (5.0%) | 3 (1.2%) | V=0.16 (p=0.167) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | ||||||||
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Diagnosis=NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 29 11 0.772 0.0609 0.6617 0.901
36 10 13 0.388 0.0826 0.2560 0.589
60 4 5 0.175 0.0744 0.0759 0.403
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 45 20 0.708 0.0555 0.607 0.825
36 17 15 0.412 0.0674 0.299 0.568
60 8 7 0.224 0.0643 0.128 0.393
Diagnosis=VIRAL
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 51 18 0.741 0.0526 0.644 0.851
36 16 22 0.367 0.0632 0.262 0.514
60 5 5 0.205 0.0664 0.109 0.387
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 32 15 0.687 0.0672 0.567 0.832
36 12 18 0.263 0.0672 0.159 0.434
60 4 2 0.203 0.0642 0.109 0.377| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis=NAFLD | 54 | 54 | 54 | 29 | 37.2 | 5.86 | 23 | 17 | 50 |
| Diagnosis=ASH | 75 | 75 | 75 | 44 | 39.3 | 4.84 | 28 | 24 | 40 |
| Diagnosis=VIRAL | 70 | 70 | 70 | 49 | 33.5 | 3.73 | 23 | 19 | 46 |
| Diagnosis=ASH & NAFLD | 50 | 50 | 50 | 36 | 33.1 | 5.05 | 25 | 17 | 32 |
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
NAFLD ASH VIRAL
ASH 0.9 - -
VIRAL 0.9 0.9 -
ASH & NAFLD 0.9 0.9 0.9
P value adjustment method: BH [1] " Exclude: Transplant >>> "
Pairwise comparisons using Log-Rank test
data: db2 and Diagnosis
NAFLD ASH VIRAL
ASH 1.0 - -
VIRAL 1.0 1.0 -
ASH & NAFLD 0.8 0.8 0.8
P value adjustment method: BH 
0.5.1 Treatment == “Curative”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Diagnosis=NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 18 1 0.955 0.0444 0.871 1.000
36 9 6 0.607 0.1174 0.415 0.887
60 4 4 0.308 0.1227 0.141 0.673
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 21 2 0.913 0.0588 0.805 1.000
36 6 7 0.523 0.1176 0.336 0.812
60 3 1 0.418 0.1327 0.225 0.779
Diagnosis=VIRAL
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 26 1 0.963 0.0363 0.894 1.000
36 11 7 0.680 0.0941 0.518 0.891
60 3 2 0.496 0.1314 0.295 0.833
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 4 0.692 0.128 0.482 0.995
36 4 3 0.404 0.149 0.196 0.831
60 1 0 0.404 0.149 0.196 0.831| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis=NAFLD | 25 | 25 | 25 | 11 | 52.0 | 8.15 | 50 | 23 | NA |
| Diagnosis=ASH | 27 | 27 | 27 | 11 | 54.5 | 9.12 | 39 | 28 | NA |
| Diagnosis=VIRAL | 28 | 28 | 28 | 13 | 50.4 | 5.50 | 53 | 48 | NA |
| Diagnosis=ASH & NAFLD | 14 | 14 | 14 | 7 | 47.4 | 12.02 | 24 | 11 | NA |
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
NAFLD ASH VIRAL
ASH 1.0 - -
VIRAL 1.0 1.0 -
ASH & NAFLD 0.9 0.9 0.9
P value adjustment method: BH 
0.5.2 Treatment == “Transplant”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 3 0 1 0 1 1
36 2 0 1 0 1 1
60 2 0 1 0 1 1
Diagnosis=VIRAL
time n.risk n.event survival std.err
12.000 4.000 2.000 0.600 0.219
lower 95% CI upper 95% CI
0.293 1.000
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 2 0 1.0 0.000 1.000 1
36 1 1 0.5 0.354 0.125 1
60 1 0 0.5 0.354 0.125 1| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis=ASH | 3 | 3 | 3 | 0 | 83.0 | 0.00 | NA | NA | NA |
| Diagnosis=VIRAL | 5 | 5 | 5 | 4 | 17.2 | 3.33 | 23 | 12 | NA |
| Diagnosis=ASH & NAFLD | 2 | 2 | 2 | 1 | 56.5 | 18.74 | 30 | 30 | NA |
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
ASH VIRAL
VIRAL 0.09 -
ASH & NAFLD 0.32 0.09
P value adjustment method: BH 
0.5.3 Treatment == “Loco-regional”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Diagnosis=NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 2 0.818 0.116 0.6192 1.000
36 1 5 0.184 0.153 0.0359 0.944
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 13 0 1.000 0.000 1.0000 1.000
36 4 7 0.417 0.142 0.2133 0.814
60 1 3 0.104 0.097 0.0168 0.646
Diagnosis=VIRAL
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 17 0 1.000 0.0000 1.0000 1.000
36 5 11 0.317 0.1167 0.1539 0.652
60 2 3 0.127 0.0836 0.0347 0.462
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 10 2 0.8182 0.1163 0.619 1.000
36 4 6 0.2727 0.1343 0.104 0.716
60 1 2 0.0909 0.0867 0.014 0.589| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis=NAFLD | 11 | 11 | 11 | 8 | 22.2 | 4.08 | 17 | 14 | NA |
| Diagnosis=ASH | 16 | 16 | 16 | 10 | 38.0 | 4.45 | 33 | 27 | NA |
| Diagnosis=VIRAL | 18 | 18 | 18 | 15 | 34.1 | 4.56 | 29 | 22 | 59 |
| Diagnosis=ASH & NAFLD | 12 | 12 | 12 | 10 | 28.5 | 5.33 | 27 | 17 | NA |
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
NAFLD ASH VIRAL
ASH 0.09 - -
VIRAL 0.22 0.60 -
ASH & NAFLD 0.60 0.55 0.60
P value adjustment method: BH 
0.5.4 Treatment == “Systemic”
Call: survfit(formula = as.formula("Surv(time = `Survival`, event = `Dead`) ~ " %+%
by))
Diagnosis=NAFLD
time n.risk n.event survival std.err
12.000 1.000 6.000 0.333 0.175
lower 95% CI upper 95% CI
0.119 0.932
Diagnosis=ASH
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 8 7 0.521 0.132 0.3166 0.857
36 5 1 0.434 0.136 0.2351 0.801
60 2 3 0.174 0.110 0.0504 0.598
Diagnosis=VIRAL
time n.risk n.event survival std.err
12.000 3.000 7.000 0.300 0.145
lower 95% CI upper 95% CI
0.116 0.773
Diagnosis=ASH & NAFLD
time n.risk n.event survival std.err lower 95% CI upper 95% CI
12 9 4 0.733 0.114 0.5405 0.995
36 3 6 0.244 0.121 0.0924 0.647
60 1 0 0.244 0.121 0.0924 0.647| records | n.max | n.start | events | *rmean | *se(rmean) | median | 0.95LCL | 0.95UCL | |
|---|---|---|---|---|---|---|---|---|---|
| Diagnosis=NAFLD | 12 | 12 | 12 | 6 | 21.6 | 7.29 | 10.5 | 8 | NA |
| Diagnosis=ASH | 16 | 16 | 16 | 12 | 25.2 | 5.50 | 13.0 | 7 | NA |
| Diagnosis=VIRAL | 10 | 10 | 10 | 8 | 13.9 | 5.81 | 4.5 | 3 | NA |
| Diagnosis=ASH & NAFLD | 15 | 15 | 15 | 11 | 26.7 | 4.56 | 25.0 | 22 | NA |
Pairwise comparisons using Log-Rank test
data: db and Diagnosis
NAFLD ASH VIRAL
ASH 0.7 - -
VIRAL 0.6 0.3 -
ASH & NAFLD 0.7 0.7 0.3
P value adjustment method: BH 
1 References
- R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.